Concurrent chemoradiation

Cisplatin + RT
Cisplatin (CDDP) 40 mg/m2 iv qw
Concurrent radiotherapy 55-75 Gy

Rose PG et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007; 25:2804 (link to the article). 

Lanciano R et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol 2005; 23:8289 (link to the article). 

Rose PG et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Eng J Med 1999; 340:1144 (link to the article).

Keys HM et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Eng J Med 1999; 340:1154 (link to the article).

Cisplatin + 5-FU + RT
Cisplatin (CDDP) 70 mg/m2 iv d1 q3w x 2 cycles
5-FU 1000 mg/m2/d civi d1-4 q3w x 2 cycles
Concurrent radiotherapy 49.3 Gy
Followed by
Cisplatin (CDDP) 70 mg/m2 iv d1 q3w x 2 more cycles
5-FU 1000 mg/m2/d civi d1-4 q3w x 2 more cycles

Peters, WA III et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18:1606 (link to the article).
 

Neoadjuvant chemotherapy (back to top)

Cisplatin + Paclitaxel
Cisplatin (CDDP) 60 mg/m2 iv d1
Paclitaxel (Taxol) 60 mg/m2 iv d1
Every 10 days x 3 cycles

Park DC et al. Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer. Gynecol Oncol 2004; 92:59 (link to the article).
 

Chemotherapy for stage IVB (metastatic) cancer (back to top)
 
Cisplatin
Cisplatin (CDDP) 50 mg/m2 iv
Q3w

Bonomi, P et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985; 3:1079 (link to the article).

Paclitaxel
Paclitaxel (Taxol) 110-200 mg/m2 iv
Q3w

McGuire, WP et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 1996; 14:792 (link to the article).

Curtin, JP et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2001; 19:1275 (link to the article).

Vinorelbine
Vinorelbine (Navelbine) 30 mg/m2 iv
Qw

Morris, M et al. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1998; 16:1094 (link to the article).

Topotecan
Topotecan (Hycamtin) 1.5 mg/m2/d iv d1-5
Q3-4w

Muderspach, LI et al. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2001; 81:213 (link to the article).

Bookman, MA et al. Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000; 77:446 (link to the article).

Cisplatin + Paclitaxel
Cisplatin (CDDP) 50 mg/m2 iv d1
Paclitaxel (Taxol) 135 mg/m2 iv d1
Q3w

Monk BJ et al. A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group (GOG) study. 2008 ASCO annual meeting. LBA5504 (link to the abstract).  

Moore, DH et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2004; 22:3113 (link to the article).

Cisplatin + Topotecan
Cisplatin (CDDP) 50 mg/m2 iv d1
Topotecan (Hycamtin) 0.75 mg/m2/d iv d1-3
Q3w x 6 cycles

Approved by FDA on 6/14/2006 

Monk BJ et al. A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group (GOG) study. 2008 ASCO annual meeting. LBA5504 (link to the abstract). 

Long HJ 3rd et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005; 23:4626. (link to the article).

Cisplatin + Vinorelbine
Cisplatin (CDDP) 50 mg/m2 iv d1
Vinorelbine (Navelbine) 30 mg/m2 iv d1, 8
Q3w x 6 cycles

Monk BJ et al. A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group (GOG) study. 2008 ASCO annual meeting. LBA5504 (link to the abstract).  

Cisplatin + Gemcitabine
Cisplatin (CDDP) 50 mg/m2 iv d1
Gemcitabine (Gemzar) 1000 mg/m2 iv d1, 8
Q3w x 6 cycles

Monk BJ et al. A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group (GOG) study. 2008 ASCO annual meeting. LBA5504 (link to the abstract).  

Carboplatin + Docetaxel
Carboplatin (Paraplatin) AUC 6 iv d1
Docetaxel (Taxotere) 60 mg/m2 iv d1
Q3w

Nagao, S et al. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol 2005; 96:805 (link to the article).